Response Genetics, Inc
RGDXQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.87K
Close$
Share Statistics
| Market cap | $3,873.00 |
|---|---|
| Enterprise Value | $9.21 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.52 |
| Beta | 4.46 |
| Outstanding Shares | 38,795,396 |
Return
| Return on Equity | 300.65% |
|---|---|
| Return on Assets | -137.72% |
| Return on Invested Capital | -222.95% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | 0.55 |
| Enterprise Value to EBIT | -0.7 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.19 |
| Debt to Equity | -2.22 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Response Genetics, Inc
96 employeesResponse Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring...